CA2864999C - Pharmaceutical composition for treatment and/or prevention of cancer - Google Patents

Pharmaceutical composition for treatment and/or prevention of cancer Download PDF

Info

Publication number
CA2864999C
CA2864999C CA2864999A CA2864999A CA2864999C CA 2864999 C CA2864999 C CA 2864999C CA 2864999 A CA2864999 A CA 2864999A CA 2864999 A CA2864999 A CA 2864999A CA 2864999 C CA2864999 C CA 2864999C
Authority
CA
Canada
Prior art keywords
antibody
cancer
ser
gin
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2864999A
Other languages
English (en)
French (fr)
Other versions
CA2864999A1 (en
Inventor
Shinichi Kobayashi
Fumiyoshi Okano
Takanori Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Publication of CA2864999A1 publication Critical patent/CA2864999A1/en
Application granted granted Critical
Publication of CA2864999C publication Critical patent/CA2864999C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2864999A 2012-02-21 2013-02-21 Pharmaceutical composition for treatment and/or prevention of cancer Active CA2864999C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012035342 2012-02-21
JP2012-035342 2012-02-21
PCT/JP2013/054312 WO2013125630A1 (ja) 2012-02-21 2013-02-21 癌の治療及び/又は予防用医薬組成物

Publications (2)

Publication Number Publication Date
CA2864999A1 CA2864999A1 (en) 2013-08-29
CA2864999C true CA2864999C (en) 2020-06-30

Family

ID=49005808

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2864999A Active CA2864999C (en) 2012-02-21 2013-02-21 Pharmaceutical composition for treatment and/or prevention of cancer

Country Status (17)

Country Link
US (1) US9260513B2 (enExample)
EP (1) EP2818481B1 (enExample)
JP (1) JP6187257B2 (enExample)
KR (1) KR102005308B1 (enExample)
CN (1) CN104114581B (enExample)
AU (1) AU2013223137B2 (enExample)
BR (1) BR112014021099A2 (enExample)
CA (1) CA2864999C (enExample)
DK (1) DK2818481T3 (enExample)
ES (1) ES2749672T3 (enExample)
HU (1) HUE046788T2 (enExample)
IN (1) IN2014KN01714A (enExample)
MX (1) MX363136B (enExample)
PL (1) PL2818481T3 (enExample)
PT (1) PT2818481T (enExample)
RU (1) RU2639522C2 (enExample)
WO (1) WO2013125630A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9416192B2 (en) * 2008-08-05 2016-08-16 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancers
PL2733492T3 (pl) 2008-08-05 2016-08-31 Toray Industries Sposób wykrywania nowotworów
US8828398B2 (en) * 2010-02-04 2014-09-09 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
PL2740489T3 (pl) * 2011-08-04 2017-06-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki
AU2012290948B2 (en) 2011-08-04 2017-05-25 Toray Industries, Inc. Method for detecting pancreatic cancer
AU2013223161B2 (en) 2012-02-21 2017-10-19 Toray Industries, Inc. Medicinal composition for treating and/or preventing cancer
WO2013147169A1 (ja) * 2012-03-30 2013-10-03 東レ株式会社 肝臓癌の治療及び/又は予防用医薬組成物
RU2649802C2 (ru) 2012-03-30 2018-04-04 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря
AU2013291047B2 (en) 2012-07-19 2018-12-06 Toray Industries, Inc. Cancer detection method
DK2876447T3 (da) 2012-07-19 2020-02-24 Toray Industries Fremgangsmåde til detektering af cancer
DK3031826T3 (en) 2013-08-09 2018-12-17 Toray Industries Pharmaceutical composition for the treatment and / or prevention of cancer
AU2017292934B9 (en) 2016-07-07 2024-08-29 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
KR20240005247A (ko) 2016-10-28 2024-01-11 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
US20210121562A1 (en) 2018-03-30 2021-04-29 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
CN114585390A (zh) 2019-06-13 2022-06-03 博尔特生物治疗药物有限公司 氨基苯并氮呯化合物、免疫缀合物及其用途
AU2020359446A1 (en) 2019-09-30 2022-04-21 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
US11654199B2 (en) 2019-10-25 2023-05-23 Bolt Biotherapeutics, Inc. Thienoazepine immunoconjugates, and uses thereof
US20230129035A1 (en) 2020-03-12 2023-04-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
US20230165957A1 (en) * 2020-03-12 2023-06-01 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
BR112022018171A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para o tratamento e/ou a prevenção de câncer, agentes aumentando a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer
EP4119160A4 (en) * 2020-03-12 2024-04-03 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3175277A1 (en) * 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3176626A1 (en) 2020-05-08 2021-11-11 David Dornan Elastase-substrate, peptide linker immunoconjugates, and uses thereof
CN116234586A (zh) 2020-08-13 2023-06-06 博尔特生物治疗药物有限公司 吡唑并氮呯免疫缀合物及其用途
WO2022270523A1 (ja) 2021-06-23 2022-12-29 東レ株式会社 癌の治療及び/又は予防のための医薬品
KR20240024803A (ko) 2021-06-23 2024-02-26 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
US20250066502A1 (en) 2021-07-27 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2023008461A1 (ja) 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び/又は予防のための医薬品
CA3227706A1 (en) 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20240051956A (ko) 2021-09-03 2024-04-22 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
US20250000995A1 (en) 2021-10-29 2025-01-02 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
US20250367307A1 (en) 2022-06-30 2025-12-04 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
AU2023329558A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4578458A1 (en) 2022-08-24 2025-07-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
AU2023329564A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4582101A1 (en) 2022-08-30 2025-07-09 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20250053841A (ko) 2022-08-30 2025-04-22 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
KR20250118852A (ko) 2022-12-23 2025-08-06 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
EP4665404A1 (en) 2023-02-14 2025-12-24 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
WO2025058000A1 (ja) * 2023-09-13 2025-03-20 東レ株式会社 癌の治療、予防及び/又は診断用医薬組成物

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
WO2001032910A2 (en) 1999-10-29 2001-05-10 Human Genome Sciences, Inc. 27 human secreted proteins
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
PL343322A1 (en) 1998-04-03 2001-08-13 Chugai Pharmaceutical Co Ltd Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
JP2002520054A (ja) 1998-07-14 2002-07-09 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
WO2000060077A2 (en) 1999-04-02 2000-10-12 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU2001261007A1 (en) 2000-03-29 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
AU2002309063B8 (en) 2001-05-11 2008-04-24 Kyowa Kirin Co., Ltd. Artificial human chromosome containing human antibody lambda light chain gene
EP1516049A4 (en) 2001-05-11 2006-01-11 Corixa Corp COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
JP2011516026A (ja) 2002-11-26 2011-05-26 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
US20050202451A1 (en) 2003-04-29 2005-09-15 Burczynski Michael E. Methods and apparatuses for diagnosing AML and MDS
AU2004256425A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
EP2361929A1 (en) 2004-01-26 2011-08-31 Debiovision Inc. Neoplasm-specific polypeptides and their use
EP2332990A1 (en) 2004-03-19 2011-06-15 Imclone LLC Human anti-epidermal growth factor receptor antibody
EP2404935A1 (en) 2004-03-30 2012-01-11 Glaxo Group Limited Immunoglobulin binding HOSM
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
AR050418A1 (es) 2005-01-21 2006-10-25 Genentech Inc Dosificacion fija de anticuerpos her
CA2598217A1 (en) 2005-02-18 2006-08-24 Marsha A. Moses Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
CA2602088C (en) 2005-03-11 2021-07-27 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer and endometrial cancer
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US8211634B2 (en) 2006-02-14 2012-07-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2008073162A2 (en) 2006-08-17 2008-06-19 Cell Signaling Technology, Inc. Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008031041A2 (en) 2006-09-07 2008-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
MY166445A (en) 2008-03-18 2018-06-27 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents,and methods of use
PL2733492T3 (pl) * 2008-08-05 2016-08-31 Toray Industries Sposób wykrywania nowotworów
MX348464B (es) 2008-08-05 2017-06-14 Toray Industries Agente inductor de inmunidad.
US9416192B2 (en) 2008-08-05 2016-08-16 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancers
EP2467401B1 (en) 2009-08-19 2017-01-18 Merck Patent GmbH Antibodies for the detection of integrin complexes in ffpe material
MX2012003404A (es) 2009-09-22 2012-09-12 Volker Sandig Procedimiento para producir moleculas que contienen estructuras de glicano especializadas.
RU2418587C1 (ru) * 2010-01-21 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") Способ лечения злокачественных опухолей головного мозга
US8828398B2 (en) * 2010-02-04 2014-09-09 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
PL2532367T3 (pl) 2010-02-04 2019-02-28 Toray Industries, Inc. Środek farmaceutyczny do leczenia i/lub zapobiegania nowotworu
PL2532364T3 (pl) 2010-02-04 2016-11-30 Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi
WO2011096528A1 (ja) * 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び/又は予防用医薬組成物
PL2532680T3 (pl) * 2010-02-04 2015-10-30 Toray Industries Kompozycja medyczna do leczenia raka i/lub zapobiegania
WO2011096533A1 (ja) * 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び/又は予防用医薬組成物
KR101271964B1 (ko) 2010-07-08 2013-06-07 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
EA201790882A1 (ru) 2010-07-26 2017-08-31 Ле Лаборатуар Сервье Способы и композиции для терапии рака печени
JP5545105B2 (ja) 2010-08-04 2014-07-09 株式会社ジェイテクト トロイダル型無段変速機のディスクの研磨方法およびトロイダル無段変速機のディスクの研磨装置
AU2012290948B2 (en) 2011-08-04 2017-05-25 Toray Industries, Inc. Method for detecting pancreatic cancer
HUE047006T2 (hu) 2011-08-04 2020-04-28 Toray Industries Anti-caprin-1 antitesteket tartalmazó gyógyászati kompozíció rák kezelésére és/vagy megelõzésére
PL2740489T3 (pl) 2011-08-04 2017-06-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki
WO2013147169A1 (ja) * 2012-03-30 2013-10-03 東レ株式会社 肝臓癌の治療及び/又は予防用医薬組成物
RU2649802C2 (ru) * 2012-03-30 2018-04-04 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря

Also Published As

Publication number Publication date
IN2014KN01714A (enExample) 2015-10-23
MX363136B (es) 2019-03-12
JP6187257B2 (ja) 2017-08-30
ES2749672T3 (es) 2020-03-23
US20150044221A1 (en) 2015-02-12
AU2013223137B2 (en) 2017-10-19
WO2013125630A1 (ja) 2013-08-29
JPWO2013125630A1 (ja) 2015-07-30
EP2818481A4 (en) 2015-10-07
PT2818481T (pt) 2019-10-25
RU2014138039A (ru) 2016-04-10
EP2818481B1 (en) 2019-08-07
HUE046788T2 (hu) 2020-03-30
MX2014009747A (es) 2014-11-14
CN104114581B (zh) 2018-11-30
BR112014021099A2 (pt) 2020-12-01
CA2864999A1 (en) 2013-08-29
CN104114581A (zh) 2014-10-22
RU2639522C2 (ru) 2017-12-21
AU2013223137A1 (en) 2014-09-11
DK2818481T3 (da) 2019-10-14
PL2818481T3 (pl) 2020-02-28
KR102005308B1 (ko) 2019-07-30
EP2818481A1 (en) 2014-12-31
KR20140130670A (ko) 2014-11-11
US9260513B2 (en) 2016-02-16

Similar Documents

Publication Publication Date Title
CA2864999C (en) Pharmaceutical composition for treatment and/or prevention of cancer
AU2013223143B2 (en) Pharmaceutical composition for treatment and/or prevention of cancer
CA2844030C (en) Pharmaceutical composition for treatment and/or prophylaxis of cancer
CA2844034C (en) Pharmaceutical composition for treatment and/or prophylaxis of cancer
AU2013223147B2 (en) Pharmaceutical composition for treatment and/or prevention of cancer
CA2844040C (en) Pharmaceutical composition for treatment and/or prophylaxis of cancer
AU2013223161B2 (en) Medicinal composition for treating and/or preventing cancer
CA2844042C (en) Pharmaceutical composition for treatment and/or prophylaxis of cancer
CA2844038C (en) Pharmaceutical composition for treatment and/or prophylaxis of cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171012